Indian Immunologicals Ltd

Hyderabad, India

Indian Immunologicals Ltd

Hyderabad, India
SEARCH FILTERS
Time filter
Source Type

Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Albany, NY, May 21, 2017 --( Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027 Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives. The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines. Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA. In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities. Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.html The pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Us 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Albany, NY, May 21, 2017 --( PR.com )-- Tetanus is a frightening disease that has plagued mankind since ancient times. Market Research Hub (MRH) has recently broadcasted a pipeline study done on this bacterial disease and titled as “Tetanus - Pipeline Review, H1 2017.” This study examines comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Moreover, its pipeline analysis by companies involved in its therapeutic development is also mentioned in detail.Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives.The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines.Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA.In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities.Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.htmlThe pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Us90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.com Click here to view the list of recent Press Releases from Market Research Hub


Karabasanavar N.S.,Veterinary College | Singh S.P.,University of Veterinary and Animal Sciences | Shebannavar S.N.,Indian Immunologicals Ltd
Food Chemistry | Year: 2014

We describe a highly specific PCR assay for the authentic identification of pork. Accurate detection of tissues derived from pig (Sus scrofa) was accomplished by using newly designed primers targeting porcine mitochondrial displacement (D-loop) region that yielded an unique amplicon of 712 base pairs (bp). Possibility of cross-amplification was precluded by testing as many as 24 animal species (mammals, birds, rodent and fish). Suitability of PCR assay was confirmed in raw (n = 20), cooked (60, 80 and 100 C), autoclaved (121 C) and micro-oven processed pork. Sensitivity of detection of pork in other species meat using unique pig-specific PCR was established to be at 0.1%; limit of detection (LOD) of pig DNA was 10 pg (pico grams). The technique can be used for the authentication of raw, processed and adulterated pork and products under the circumstances of food adulteration related disputes or forensic detection of origin of pig species. © 2013 Elsevier Ltd. All rights reserved.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-SICA | Phase: KBBE-2008-1-3-02 | Award Amount: 4.09M | Year: 2009

Foot-and-mouth disease (FMD) is one of the worlds most infectious diseases of livestock and continues to pose a significant threat to endemic and free regions alike. The impact of FMD on society and international trade is high, thereby demanding stringent prevention, surveillance and control plans taken up in crisis preparedness plans. On the other hand, there is a global increased demand for animal welfare and ethical considerations necessitating a decreased reliance on eradication of animals to control FMD virus (FMDV) spread, and on the use of animals for the regulatory testing of veterinary products. The project seeks to balance these apparently contracting viewpoints by addressing specific gaps in our knowledge on all aspects of FMD control to enable implementation of enhanced animal-sparing vaccine-based control strategies tailored to the needs of free and endemic settings. Consequently, four main objectives have been identified, including (i) the improvement of the quality of existing FMD vaccines and diagnostics, (ii) the refinement and replacement of in vivo FMD vaccine quality tests, (iii) the development of new generation FMD vaccines and diagnostics by applying cutting edge technologies, and (iv) the enhancement of our knowledge on FMDV spread and transmission following the use of high-potency monovalent or multivalent vaccines. The role of wildlife (buffalo, gazelles and wild boar) in FMDV maintenance and transmission will also be investigated. The project consists of seven different, yet interlinked, work packages (WP) each addressing one of the items listed in the Work Programme topic KBBE-2008-1-3-02, and led by renowned WP leaders with years of relevant experience in the field of FMD. As such, significant progress towards the objectives of the Communitys Animal Health Strategy (2007-2013), the European Technology Platform for Global Animal Health, and the Global Roadmap for improving the Tools to Control FMD in Endemic Settings will be achieved.


— The report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Hepatitis B - Pipeline Review, H2 2016 addition with 129 market data tables and 17 figures, spread across 389 pages is available at http://www.reportsnreports.com/reports/781956-hepatitis-b-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Companies Discussed /Mentioned in this Research: Abivax , AiCuris GmbH & Co KG, AIMM Therapeutics BV, Akshaya Bio Inc, Alnylam Pharmaceuticals Inc, AlphaMab Co, Altimmune Inc,Altravax Inc, Amarna Therapeutics, Arbutus Biopharma Corp, Arcturus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Assembly Biosciences Inc, Beijing Kawin Technology Share-Holding Co Ltd, Beijing Minhai Biotechnology Co Ltd, Benitec Biopharma Ltd, Chong Kun Dang Pharmaceutical Corp, Dicerna Pharmaceuticals Inc, Ensemble Therapeutics Corp, F. Hoffmann-La Roche Ltd, Indian Immunologicals Ltd, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, ISA Pharmaceuticals BV, Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=781956 premium report price at US$2000 for a single user PDF license). Scope • The report provides a snapshot of the global therapeutic landscape of Hepatitis B • The report reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved Hepatitis B therapeutics and enlists all their major and minor projects • The report assesses Hepatitis B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type • The report summarizes all the dormant and discontinued pipeline projects • The report reviews latest news related to pipeline therapeutics for Hepatitis B Reasons to buy • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Identify and understand important and diverse types of therapeutics under development for Hepatitis B • Identify potential new clients or partners in the target demographic • Develop strategic initiatives by understanding the focus areas of leading companies • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics • Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline For more information, please visit http://www.reportsnreports.com/reports/781956-hepatitis-b-pipeline-review-h2-2016.html


Sarkar S.,University of Alberta | Tang X.L.,University of Alberta | Das D.,University of Alberta | Das D.,Indian Immunologicals Ltd | And 3 more authors.
PLoS ONE | Year: 2012

The re-emergence of tuberculosis (TB) as a global public health threat highlights the necessity of rapid, simple and inexpensive point-of-care detection of the disease. Early diagnosis of TB is vital not only for preventing the spread of the disease but also for timely initiation of treatment. The later in turn will reduce the possible emergence of multi-drug resistant strains of Mycobacterium tuberculosis. Lipoarabinomannan (LAM) is an important non-protein antigen of the bacterial cell wall, which is found to be present in different body fluids of infected patients including blood, urine and sputum. We have developed a bispecific monoclonal antibody with predetermined specificities towards the LAM antigen and a reporter molecule horseradish peroxidase (HRPO). The developed antibody was subsequently used to design a simple low cost immunoswab based assay to detect LAM antigen. The limit of detection for spiked synthetic LAM was found to be 5.0 ng/ml (bovine urine), 0.5 ng/ml (rabbit serum) and 0.005 ng/ml (saline) and that for bacterial LAM from M. tuberculosis H37Rv was found to be 0.5 ng/ml (rabbit serum). The assay was evaluated with 21 stored clinical serum samples (14 were positive and 7 were negative in terms of anti-LAM titer). In addition, all 14 positive samples were culture positive. The assay showed 100% specificity and 64% sensitivity (95% confidence interval). In addition to good specificity, the end point could be read visually within two hours of sample collection. The reported assay might be used as a rapid tool for detecting TB in resource constrained laboratory settings. © 2012 Sarkar et al.


Global Foot and Mouth Disease (FMD) Vaccines Market Analysis: Animals, Vaccines, Growth Trends and Forecast to 2020, New Report by iHealthcareAnalyst, Inc. Foot and Mouth Disease (FMD) Vaccines Market by Animal Types (Cattle, Pigs, Sheep and Goats, Others) and FMD Vaccine Types (Conventional – Al(OH)3-based and Oil-based, and Emergency Vaccines) 2016-2020. Maryland Heights, MO, February 21, 2017 --( Browse Foot and Mouth Disease (FMD) Vaccines Market by Animal Types (Cattle, Pigs, Sheep and Goats, Others) and FMD Vaccine Types (Conventional – Al(OH)3-based and Oil-based, and Emergency Vaccines) 2016-2020 at https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/. Foot and Mouth Disease (FMD) is caused by seven different types of serotypes: O, A, C, Asia 1 and Southern African Territories (SAT) 1, 2 and 3. The major symptoms of FMD are high fever, sudden weight loss, increased death rate in newborn animals, low conception rate, painful lesions in and around mouth, lips and feet, and excessive salivation. Cloven-hoofed animals especially cattle, pigs, sheep and goats are susceptible to FMD. Vaccination of susceptible animals against foot and mouth disease is a proven strategy for helping to combat the disease since the virus is highly infectious and can be spread by infected animals. The global foot and mouth disease vaccines market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market and also forecasts growth trends (CAGR% - 2016 to 2020). The report also covers the major companies operating in the market and provides detailed market analysis of the different animal types (cattle, pigs, sheep and goats, others) and FMD vaccine types (conventional – Al(OH)3-based and oil-based, and emergency vaccines) available in the global market. The global foot and mouth disease vaccines market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global foot and mouth disease vaccines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global foot and mouth disease vaccines market and included in this report are Agrovet Co., Bayer AG, Biogenesis Bagó, Brilliant Bio Pharma Limited, Indian Immunologicals Ltd., Inova Biotechnologia, Intervac (Pvt.) Ltd., Merial, and Merck Animal Health (MSD). To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, February 21, 2017 --( PR.com )-- The Foot and Mouth Disease Vaccines market is estimated to reach USD 800 Million in 2020, expanding at a CAGR of 4.6% from 2016 to 2020, due to increased demand for meat and dairy products worldwide. The FMD vaccines traditionally represents the largest share of the veterinary vaccine market worldwide in terms of sales of the entire livestock biological business.Browse Foot and Mouth Disease (FMD) Vaccines Market by Animal Types (Cattle, Pigs, Sheep and Goats, Others) and FMD Vaccine Types (Conventional – Al(OH)3-based and Oil-based, and Emergency Vaccines) 2016-2020 at https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/.Foot and Mouth Disease (FMD) is caused by seven different types of serotypes: O, A, C, Asia 1 and Southern African Territories (SAT) 1, 2 and 3. The major symptoms of FMD are high fever, sudden weight loss, increased death rate in newborn animals, low conception rate, painful lesions in and around mouth, lips and feet, and excessive salivation. Cloven-hoofed animals especially cattle, pigs, sheep and goats are susceptible to FMD. Vaccination of susceptible animals against foot and mouth disease is a proven strategy for helping to combat the disease since the virus is highly infectious and can be spread by infected animals.The global foot and mouth disease vaccines market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market and also forecasts growth trends (CAGR% - 2016 to 2020). The report also covers the major companies operating in the market and provides detailed market analysis of the different animal types (cattle, pigs, sheep and goats, others) and FMD vaccine types (conventional – Al(OH)3-based and oil-based, and emergency vaccines) available in the global market. The global foot and mouth disease vaccines market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global foot and mouth disease vaccines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global foot and mouth disease vaccines market and included in this report are Agrovet Co., Bayer AG, Biogenesis Bagó, Brilliant Bio Pharma Limited, Indian Immunologicals Ltd., Inova Biotechnologia, Intervac (Pvt.) Ltd., Merial, and Merck Animal Health (MSD).To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/foot-and-mouth-disease-vaccines-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill DriveMaryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


Sathish K.,Indian Immunologicals Ltd | Sriraman R.,Indian Immunologicals Ltd | Subramanian B.M.,Indian Immunologicals Ltd | Rao N.H.,Indian Immunologicals Ltd | And 3 more authors.
Vaccine | Year: 2011

Coccidiosis is an economically important disease affecting poultry industry and remains one of the major problems globally. Developing a cost effective sub-unit vaccine may help mitigate loss in the industry. Here, we report expressing one of the microneme proteins, EtMIC2 from Eimeria tenella in tobacco using Agrobacterium-mediated transient expression. The ability of plant expressed recombinant EtMIC2 in eliciting both humoral and cell-mediated immune responses were measured in the immunized birds. The protective efficacy in the vaccinated birds against a homologous challenge was also evaluated. Birds immunized with plant expressed EtMIC2 showed good sero-conversion, reduced oocyst output and increased weight gain when compared to control birds. Our data indicate that use of plant expressed recombinant EtMIC2 in birds was safe and had the potential in imparting partial protection in chickens against homologous challenge. © 2011 Elsevier Ltd.


Hanumantha Rao N.,Indian Immunologicals Ltd | Baji Babu P.,Indian Immunologicals Ltd | Rajendra L.,Indian Immunologicals Ltd | Sriraman R.,Indian Immunologicals Ltd | And 3 more authors.
Vaccine | Year: 2011

The major capsid protein (L1) of human papillomaviruses (HPV) expressed in heterologous systems assembles into virus-like particles (VLPs). We report cloning and expression of codon optimized HPV L1 genes of the two high-risk HPV types 16 and 18 in methylotropic yeast, Pichia pastoris. The VLPs produced in P. pastoris were subjected to three step purification method involving density gradient centrifugations and size exclusion chromatography. The enriched VLPs were characterized using conformation-specific monoclonal antibodies in ELISA and by transmission electron microscopy. Mice immunized with a bivalent HPV16 and HPV18 VLPs developed high serum antibody titers to both HPV types that persisted for 190 days post vaccination. Serum of mice immunized with the HPV-VLP preparations could neutralize homologous pseudoviruses in an in vitro assays. Our results demonstrate that the L1 proteins expressed in P. pastoris fold properly as evidenced by assembly into VLPs and induction of type-specific neutralizing antibody response in mice. This work constitutes a step towards developing an alternate production platform for generating an affordable HPV vaccine to meet the needs of developing countries. © 2011 Elsevier Ltd.


Trangadia B.,Indian Immunologicals Ltd. | Rana S.K.,Indian Immunologicals Ltd. | Mukherjee F.,Indian Immunologicals Ltd. | Srinivasan V.A.,Indian Immunologicals Ltd.
Tropical Animal Health and Production | Year: 2010

This study was carried out to investigate the prevalence of bovine brucellosis and infectious bovine rhinotracheitis (IBR) in organized dairy farms with history of abortion in India. ELISA and Rose Bengal Plate Test (RBPT) were used to detect the seropositive animals and the test results indicated that 22.18% and 13.78% animals were declared as sero-positive by ELISA and RBPT, respectively. Milk Ring Test (MRT) was carried out only in one farm and 12.82% of the tested animals were turned positive. Culture examination analysis of milk samples, two animals revealed the presence of organisms indistinguishable from Brucella spp. The organism was confirmed as brucella by morphological characteristics and biochemical tests. An overall sero-prevalence of antibodies against IBR was found to be 60.84%. None of the genital and nasal swab samples was found to be positive for presence of bovine herpesvirus -1 (BHV-1) on repeated passage in Madin-Darby Bovine Kidney (MDBK) cell lines. Brucella and IBR considered as the causal agent for abortions in these farms. The present study indicates the urgent need and the necessity for control of these infectious diseases which cause heavy economic losses to the organized farms. © Springer Science+Business Media B.V. 2009.


Patent
Indian Immunologicals Ltd | Date: 2011-05-04

The present disclosure relates to chimeric tymovirus-like particles (TVLPs) comprising a fusion protein that further comprises of a first protein that is a truncated tymovirus coat protein and a second protein. These chimeric TVLPs are useful as antigens. The present disclosure provides a highly efficient means for differentiating Foot and Mouth Disease Virus (FMDV) infected animals from vaccinated animals. The present disclosure further provides a process for the production of chimeric TVLPs and a diagnostic kit for the determination of specific antibodies of FMDV to differentiate FMDV infected from vaccinated animals. The present disclosure also provides the use of the chimeric TVLPs for diagnostic purposes.

Loading Indian Immunologicals Ltd collaborators
Loading Indian Immunologicals Ltd collaborators